Global avian influenza vaccines market is anticipated to witness significant growth in the forecast period due to rising prevalence of influenza due to unhealthy eating habits. Avian influenza is a disease (infection or flu) caused by avian bird. This infection is prevalent in aquatic birds and can infect the animal, poultry, and humans too. Avian influenza vaccination help control the infection among birds and others.

The key drivers of avian influenza vaccines market are rising incidences of infections among poultry animal and birds and demand from hospitals and clinics for treating the infection in humans. Increase in awareness regarding pandemic influenza and seasonal outbreak in the infection are emerging trends observed in the market. Growing research and development activities, avian influenza vaccines market is expected to offer opportunities to the market players for introducing newer vaccines.

Market is categorized on the basis of type, distribution channel, application, and geography. On the basis of type, market is divided into type H9, type H5, and others. H9 and H5 segments are expected to lead the market due to increasing vaccines against them.

Get Sample Copy of this Report @

https://www.millioninsights.com/industry-reports/avian-influenza-vaccines-market/request-sample

Based on distributing channel, market is divided into distribution channel and direct channel. Distribution channel is expected to lead the market due to preference and increasing developments in the sector. In terms of application, market is bifurcated into duck and goose, chicken, and others. Chicken segment accounts for larger market share due to increasing population of chicken and high prevalence of influenza virus in them as compared to others.

Geographically, market is segmented as North America, South Africa, Europe, Asia Pacific, and Middle East & Africa. Asia Pacific is expected to dominate the avian influenza vaccines industry owing to high prevalence of influenza virus in birds and poultry animals. North America is also expected to dominate the market in terms of both volume and value.

The leading players in avian influenza vaccines market comprise Elanco (Lohmann), FATRO, QYH Biotech, Merial, CEVA, DHN, HVRI, Yebio, Merck Animal Health, Kyoto Biken, Medion, Avimex Animal Health, Vaksindo, ChengDu Tecbond, Zoetis, CAVAC, Ringpu Biology, Bio-Labs, JOVAC, and Sindh Poultry Vaccine Centre.

Browse Related Category Market Reports @

https://www.millioninsights.com/industry/pharmaceuticals

Influenza Vaccine Market is expected to reach more than US$ 1 Billion across the 5 major markets (5MM) of the France, Germany, Italy, Spain and United Kingdom by the year end of 2022.

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against Influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries.

Request for a sample of report @

https://mindaspiremarketresearch.com/request-sample/report/influenza-vaccines-market-in-top-five-european-countries

United Kingdom influenza vaccine market is the most attractive of those covered in the report. The United Kingdom market for influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. Germany will be the second–largest market for influenza vaccine which is expected to grow at a CAGR of XX% by 2022. France is expected to be third largest influenza vaccine market being followed by Italy by the end of the forecasted period.

Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into influenza vaccine sales forecast for the top five countries, comprising the UK, France, Italy, Spain and Germany until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players

in the influenza vaccine market, such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of influenza vaccine market.

Five Major European Markets(5MM) covered in the report are as follows:

1. United Kingdom
2. France
3. Italy
4. Spain
5. Germany

Major and Promising Vaccines covered in the report are as follows:

1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4. Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8. FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850
14. Flucelvax Quadrivalent
15. Afluria Quadrivalent
16. Agrippal
17. Fluad
18. Fluvirin
19. Fluvax

Ask an Analyst @

https://mindaspiremarketresearch.com/inquire/report/influenza-vaccines-market-in-top-five-european-countries

Key Companies Covered in the Report are as follows:

1. Sanofi Pasteur
2. GlaxoSmithKline(GSK)
3. Seqirus
4. AstraZenecca
5. Protein Sciences Corporation
6. Novavax
7. Daiichi–Sankyo
8. Mitsubishi Tanabe Pharma
9. BiondVax Pharmaceuticals Ltd
10. VaxInnate

Influenza commonly referred as flu is a contagious respiratory illness caused by influenza virus. The virus can cause mild to severe illness, resulting in serious outcomes such as hospitalization or death. Geriatric population, pregnant women, and people with chronic health conditions are at high risk of serious flu complications. Influenza virus is responsible for seasonal epidemic events and are classified into two types of influenza virus, including A and B. The influenza vaccines market is expected to gain significant traction as number of manufacturers are increasing the production capacity of vaccines for use in the U.S. market for the 2017–2018 influenza season using the innovative technologies such as egg-based, cell-based, and recombinant technologies.

Request Sample Copy Of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1127

Market Dynamics

The major factors driving growth of the U.S. influenza vaccines market include rapid advancements in technology for development of new vaccines such as recombinant and cell-based technologies, resulting in increasing production of the vaccines. Influenza flu vaccination have the potential to reduce the risk of flu-associated hospitalization among children and adults. According to the Centers for Disease Control and Prevention, 2015, flu vaccinations prevented an around 1.9 million flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated hospitalizations, representing 6.5% lowering of disease burden in the U.S. Moreover, the collaborative efforts of various government bodies such as U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) with the private sector has led to development of improved influenza vaccine technologies in the U.S. This in turn, has improved influenza pandemic preparedness in the country.

Key features of the study:

• This report provides in-depth analysis of U.S. influenza vaccines market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2016 as the base year

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players

• It profiles leading players in the U.S. influenza vaccines market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans

• Key companies covered as a part of this study include Sanofi Pasteur, Seqirus Vaccines Ltd., GlaxoSmithKline Plc., and Medimmune

Detailed Segmentation:

• U.S. Influenza Vaccines Market, By Vaccine Type:

  • Trivalent Vaccines

  • Quadrivalent Vaccines

• U.S. Influenza Vaccines Market, By Virus Type:

  • Influenza Virus Type A

  • Influenza Virus Type B

• U.S. Influenza Vaccines Market, By Age Group:

  • Pediatrics

  • Adults

• Company Profiles

   

Government initiatives to tackle such events is a major factor propelling growth of the U.S. influenza vaccine market

The government agencies in the U.S. are focusing on collaborations in order to increase the supply of influenza vaccines. For instance, the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH) have partnered with the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to support the advanced development of new and better influenza vaccines, as a part of inter-agency government effort in the U.S.

Click To Read More On U.S. Influenza Vaccines Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Influenza is contagious respiratory disease that is caused by influenza viruses and can lead to hospitalization and even death in certain severe cases. Influenza virus infect the respiratory tract (nose, throat, and lungs) in humans. Seasonal influenza detected year-round and the virus is most common during the influenza season especially in fall and winter months. Moreover, the exact timing and duration of influenza season varies, however influenza activity often begins in winter months. At various geographical regions, influenza infection exist at a low level throughout the year, however its shows seasonal increase typically during the winter months. A seasonal influenza flu vaccine aids in reducing the risk of getting infected with seasonal flu and prevent its spreading throughout the year.

Some of the key players in the seasonal influenza vaccines market includes Sanofi S.A., CSL Limited, GlaxoSmithKline Plc., and Medimmune, LLC. Key players in the market are involved in strategic mergers and acquisitions, to cater to increasing demand for these vaccines. For instance, in August 2017, Sanofi Pasteur acquired Protein Sciences Corporation, thus adding Flublok products to its portfolio — the only FDA approved recombinant protein-based influenza vaccine. With the acquisition, Sanofi expanded its influenza vaccine portfolio and its presence in the global vaccines market.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1604

The 2017–2018 recommendations by the Advisory Committee on Immunization Practices (ACIP) mentions routine annual influenza vaccination for everyone aged 6 months and older with either inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV). A high variability and broad host specificity of influenza viruses are the major causes of repeated influenza infections. Moreover, virus neutralizing antibodies induced by various vaccines are strain specific, which leads to vaccinations being updated each year. To tackle this issue, various government and private research organizations are engaged in developing novel vaccines to increase efficacy of these vaccines.

Seasonal Influenza Vaccines Market – Drivers

Increasing incidence of seasonal influenza infection in various geographies is expected to be a major driving factor for growth of global seasonal influenza vaccines market. Rising pandemic events of influenza virus and their severity attributed to the genetic diversity of influenza virus is also another factor aiding in growth of the market. According to the World Health Organization (WHO), 2015, around 233 million outpatient visits, 5.2 million hospital admissions, and 7.4 million deaths are expected if a pandemic case were to occur, globally. Also, the Centers for Medicare & Medicaid Services (CMS) provides reimbursement covering 100% of the costs of one seasonal influenza virus vaccinations per influenza season, and it also covers the seasonal influenza virus vaccinations. Thus, favorable reimbursement is also expected to positively affect adoption rates of seasonal influenza vaccines, thus propelling the market growth.

Moreover, influenza flu vaccination enables to reduce the risk of flu-associated hospitalization among adult and pediatric patients. For instance, according to the Centers for Disease Control and Prevention, 2015, flu vaccinations prevented around 1.9 million flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated hospitalizations, representing 6.5% lowering of disease burden in the U.S.

Seasonal Influenza Vaccines Market – Taxonomy

By Vaccine Type

By Virus Type

By Age Group

By End User

Hospitals

Seasonal Influenza Vaccines Market – Regional Analysis

Geographically, global seasonal influenza vaccines market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds the dominant position in seasonal influenza vaccines market, owing to increasing research and development studies by key market players, to develop novel influenza vaccines and increasing burden of seasonal influenza infection in the region.

Click To Read More On Seasonal Influenza Vaccines Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.